| Literature DB >> 24381533 |
Suresh Kumar Kailasa1, Hui-Fen Wu2.
Abstract
Recently, mass spectrometric related techniques have been widely applied for the identification and quantification of neurochemicals and their metabolites in biofluids. This article presents an overview of mass spectrometric techniques applied in the detection of neurological substances and their metabolites from biological samples. In addition, the advances of chromatographic methods (LC, GC and CE) coupled with mass spectrometric techniques for analysis of neurochemicals in pharmaceutical and biological samples are also discussed.Keywords: CE-MS; GC-MS; LC-MS; MALDI-MS.; Neurochemicals
Year: 2013 PMID: 24381533 PMCID: PMC3744906 DOI: 10.2174/1570159X11311040007
Source DB: PubMed Journal: Curr Neuropharmacol ISSN: 1570-159X Impact factor: 7.363
Classification of Neurodrugs and their Generic Names, Molecular Weights, Structures and Trade Names
LC – MS Methods for the Identification of Neurochemicals and their Metabolites in Various Samples
| Name of Neurochemicals | Matrix | Sample Preparation | Chromatographic Technique | Detection Technique | Limit of Detection | Refs. |
|---|---|---|---|---|---|---|
| DMI, IM, NOR, AMT, CL | Plasma | SDME | LC- AA buffer (0.01 mM,
pH 5.50) : ACN (50:50, | ESI-MS | 0.1 | [ |
| AM, MA | Plasma | SDME | LC- ACN-water | ESI-MS/MS | 0.3 - 0.04 | [ |
| FLU, PXT, SRT, FLV, CIT, MIL, VEN, MIR, NF, DMCTP, DDMCTP, DMVEN, DMMIR | Blood | LLE | LC - ACN/AF buffer (4 mM, pH 3.2) | ESI-MS/MS | 10 | [ |
| AMT, CTP, CL, DMI, DMCTP, DMCL, DMDS, DMD, DMFLU, DMVEN, DDMCTP, DOS, DOX, FLU, FLV, IM, MAT, MIA, MIR, MOC, NOR, PXT, RBX, SRT, TRZ, VEN | Plasma | LLE | LC | ESI-MS/MS | LOQ:
2.5 -10 | [ |
| AMT, NOR | Rat plasma | LLE | LC - AA(0.6% formic acid)-ACN (60:40, | ESI-MS | ~1.0 | [ |
| FLU, CTP, PXT, VEN | Plasma | SPE | LC- water (formic acid 0.6 mM- AA: 30 mM)-ACN (35:65, | ESI-MS | 0.1 - 0.5 | [ |
| VEN and its three metabolites ODV, NDV DDV | Human plasma | LLE | LC- water (AA-30mM, formic acid- 2.6 mM and TFA-0.13 mM) and ACN (60:40, | ESI-MS | 0.2 - 0.4 | [ |
| VEN and its metabolite ODV | Plasma | - | UPLC- AA-30 mM -MeOH (15:85, pH 6.0) | ESI-MS | 1.0 | [ |
| VEN, ODV | Plasma | LLE | LC - AA (10 mM) and MeOH | ESI-MS | LOQ: 0.2 | [ |
| ENP, ENPT | Plasma | LLE | LC- MeOH-water-formic acid (62:38:0.2, | ESI-MS/MS | LOQ: 0.63 | [ |
| ENP, ENPT | Plasma | LLE | LC | ESI-MS/MS | LOQ: 0.1 | [ |
| ENP, ENPT | Plasma | SPE | LC | ESI-MS/MS | LOQ: 0.2, 1.0 | [ |
| ENP, ENPT | Plasma | SPE | LC | ESI-MS/MS | 0.064 | [ |
| ACh, Ch, iso-ACh | Rat brain | Microdialysis | LC-IC- AF, AA and ACN | ESI-MS/MS | 0.2 - 0.6 | [ |
| ACh, Ch, acetyl-β-methylcholine | Rat brain dialysates | Microdialysis | LC-IC | ESI-MS/MS | 0.05, 3.75 | [ |
| ACh | Rats | Microdialysis | HILIC | ESI-MS/MS | 0.075 | [ |
| ACh | Rat brain | Microdialysis | LC-2% of ACN and 0.05% of TFA | APCI-MS/MS | LOQ:0.15 | [ |
| [Met]enkephalin and [Leu]enkephalin | Freely-moving rats. | Microdialysis | LC- | ESI-MS/MS | 0.001, 0.002 | [ |
| Endogenous ACh | Rodent brain | Microdialysis | LC- | ESI-MS/MS | 0.04 | [ |
| Endogenous opioid peptides | Rat striatum | Microdialysis | LC | ESI-MS/MS | 5.0 | [ |
| DA, 5-HT, NE | - | Microdialysis | LC | ESI-MS/MS | 0.2, 1.0, 0.9 | [ |
| GABA, Glu | Brain | Microdialysis | HILIC - 0.1% formic acid in water and ACN | ESI-MS/MS | 1.0 | [ |
| ACh, Ch | Rat and mouse brain | Microdialysis | LC- AF (20 mM, pH 3.3) and ACN (20:80) | ESI-MS/MS |  0.02, 10 | [ |
| ACh | Rat brain | Microdialysis | LC | ESI-MS/MS | 1.4 | [ |
| NMN, MN, 3-MT | Plasma | SPE | LC | ESI-MS/MS | < 0.1 | [ |
| MN, NMN | Plasma | SPE | LC | ESI-MS/MS | - | [ |
| MN, NMN | Urine | SPE | LC | ESI-MS/MS | 2.5 | [ |
| 5-HT, and its precursors, 5-HTP, TP | Chocolate samples | Acidic extraction | cLC-ACN and AF
(5 mM, pH 4, 3:97, | ESI-MS/MS | 0.01, 0.11 | [ |
| 5-HT, MEL, trans- and cis-piceid, and trans- and cis-resveratrol | Fruits | LLE | HPLC- ACN and water with 0.1% formic acid | ESI-MS | - | [ |
| 5-HT | Plasma | LLE | LC-MeOH | ESI-MS/MS | 1.5 | [ |
| CTP, FLU, FLV, PXT, SRT, and their main active metabolites DMCTP, NF | Plasma | LLE and SPE | LC- AA (50 mM, pH 8.1) and ACN | ESI-MS/MS | - | [ |
| Glu, GABA, Ch, ACh, DA, 5-HIAA, 5-HT, DOPAC, HVA | Rat brain | - | UHPLC | ESI-MS/MS | LOQ: 2.440 | [ |
| 5-HT, DA, 5-HIAA | Urine | - | - | nano-ESI-MSn | 9 - 12.9 | [ |
| GLUs, 5-HT, DA, 5-HIAA, DOPAC, HVA | Rat brain | Microdialysis | LC | ESI-MS/MS | - | [ |
| DA and its phase I and phase II metabolites | Rat and mouse brains | Microdialysis | LC | ESI-MS/MS | 0.8 | [ |
| Neuroleptics clozapine, flupentixol, haloperidol, penfluridol, thioridazine, and zuclopenthixol | Hair samples | SPE | LC - Solvent A, (AF (1 mM)/0.1% formic acid, pH 3) and solvent B (ACN/0.1% formic acid) | ESI-MS/MS | 0.05 | [ |
| MP, MAM, COD, COC, BZE | Hair | SPE | - | ESI-MS/MS | 0.004 -0.039 | [ |
| MD, EDDP, COC BZE, AMP, MP, COD | Human umbilical cord | SPE | LC | ESI-MS | <0.0025 | [ |
| MP, COD, AMP, EME, BZE, COC, CCE, AM, MA, MDOAM, MDOMAM, MDOEAM | Blood | SPE | LC- AF (20 mM, pH 2.8) (solvent A) and ACN/solvent A (90:10, | ESI-MS/MS | - | [ |
| LSD, iso-LSD and the metabolite 2-oxo-3-hydroxy-LSD | blood | LLE | LC | ESI-MS/MS | LOQ: 0.01 | [ |
| LSD and iso-LSD | Blood and urine | LLE | LC | ESI-MS/MS | LOQ: 0.02 | [ |
| PCP | Oral fluid | SPE | LC | APCI-MS/MS | LOQ; 5 | [ |
| PCP, AM, MC, MA, MDOAM, MDOEAM, MDOMAM, COC, BZE, KT, PSC | Oral fluid | MSPE | LC | ESI-MS/MS | LOQ:
 0.3 - 4.9 | [ |
| THC, 11-OH-THC, THCCOOH, CBN, CBD, THC-GLU, THCCOOH-GLU | Urine | LLE | LC- AA (10 mM, pH 6.15) and 15% MeOH in ACN | ESI-MS/MS | - | [ |
| CB substances (CP 47, 497) | Urine | LLE | LC- | ESI-MS/MS | 10 | [ |
| THC, 11-OH-THC, THCCOOH, CBN, CBD | Blood | LLE | LC- water and ACN, both containing 0.2% formic acid | ESI-MS/MS | 0.25 - 0.80 | [ |
| NIC, OH-COT, CNO, CAF, ARC | Breast milk | LLE | LC- AF (50mM, pH 5.0) and ACN | ESI-MS/MS | 1.6 - 16.0 | [ |
| NIC, COT, trans-OHCOT | Meconium samples | SPE | LC | ESI-MS/MS | - | [ |
| NIC, COT, trans-OHCOT, NC | Human plasma | - | LC | ESI-MS/MS | - | [ |
| NIC-GLU, CNO, trans-OH-COT, NC, trans-NICO, COT, NN, NIC, AT, AB, COT-GLU | Human plasma and urine | SPE | LC | ESI-MS/MS | 1.0 - 2.5 | [ |
| NIC, COT, trans-OH-COT, VCL | Plasma | SPE | LC - AA (10 mM, pH 3)/ACN | ESI-MS/MS | < ng/mL | [ |
| NIC, COT, trans-OH-COT, NNO, CNO | Urine | LLE | LC | ESI-MS/MS | LOQ: 10 | [ |
| Nicotine-N-glucuronidation | Liver | LLE | LC | ESI-MS/MS | LOQ: 10 | [ |
| NIC, COT, NN, NC, NIC-GLU, COT-GLU, NNO, CNO, trans-OH-COT, AB, AT | Rat brain | SPE | LC | ESI-MS/MS | < 0.025 | [ |
| NIC, NN, AT, AB, COT | Urine | SPME | LC- AF (5 mM)/MeOH (55/45, | ESI-MS/MS | 0.015-0.040 | [ |
| NIC, COT and their metabolites | Urine | - | UPLC | ESI-MS/MS | 0.7, 0.4 | [ |
| NIC and its metabolites | Dog hair | LLE | IC | FT-MS | 0.05- 0.23 | [ |
| Neurochemicals | Brain | - | HPLC | ESI-MS/MS | 0.05 -250 | [ |
ng/mL;
µg/L;
fM;
nM;
ng/mg.
An Overview of GC-MS Methods for the Analysis of Neurochemicals in Biological Samples
| Name of the Neurological Drug | Matrix | Sample Preparation | Chromatographic Technique | Detection Technique | Limit of Detection | Ref. |
|---|---|---|---|---|---|---|
| AM, MA | Blood | SPE | GC | CI | 1.0 | [ |
| AM, MA, MDOAM, MDOMAM, MDOEAM | Oral fluid | - | GC | CI | - | [ |
| Allopregnanolone (5α,3α-THP) and related neurosteroids | CSF and plasma | SPE | GC | ECNCI/MS | <pg/mL | [ |
| THC, AM, MA, COC, EtOH | Saliva | SPME | GC | FID | LOQ: 0.01 - 5.0a | [ |
| COC, BZE, CCE | Human hair | SPME | GC | FID | 0.1 | [ |
| DA, (R)/(S)- SAL, NSAL | Human brain | SPE | GC | - | - | [ |
| COD, MP, AMP | Human hair | HS-SPME | GC | - | LOQ: 0.005 -0.01 | [ |
| THC, CBD, CBN | Human hair | HS-SPME | GC | - | 0.007-0.031 | [ |
| AM, MA, MDOAM, MDOMAM, MDOEAM, KT, NK, MP, COD, AMP | Human hair | SPE | GC | EI and NCI | 0.03 -
0.08 | [ |
| PCP | Blood and urine | - | GC | SIOMS | 0.05 | [ |
| MDOAM, MDOMAM, MDOEAM, MBDB | Hair | HS-SPME | GC | PCI | <0.7 | [ |
| PCP | Blood and urine | SPE | GC | - | - | [ |
| THC, 11-OH-THC, THCCOOH | Blood | LLE | GC | NCI-MS/MS | <0.5 | [ |
| THC, CBD, CBN, 11-OH-THC, THCCOOH | Oral fluid | SPE | GC | 2D-GCMS | < 7500 | [ |
| THC, CBD, CBN | Human hair | HF-LPME | GC | MS/MS | 500-15000 | [ |
| THC, CBD, CBN, 11-OH-THC, THCCOOH | Blood | LLE | GC | MS/MS | 0.25 | [ |
| NIC | Hair | LLE | GC | MS | <0.04 | [ |
| NIC, COT | Urine | LLE | GC | MS | 0.20 | [ |
| NIC, COT, NC, trans-OHCOT | Human oral fluid | SPE | GC | EI-MS | < 5 | [ |
| CAF | Human serum | SPME | GC | MS | 100 | [ |
ng/mL;
µg/L;
ng/mg.
CE-MS Methods for the Analysis of Neurological Chemicals in Biofluids
| Name of the Neurological Drug | Matrix | Technique | LOD | Refs. |
|---|---|---|---|---|
| 20 antidepressants | Plasma | SPE-CE-ESI-TOF-MS | 0.5-1.0 | [ |
| MA, MDOAM, MDOMAM, MDOEAM, MD, COC, MP, COD, AMP, BZD | Blood | LLE-CZE-ESI-TOF MS | 2-10 | [ |
| AMP, MP, AM, MDOAM, MDOMAM, MDOEAM, BZD, EP, COC | Hair | LLE- CZE-ESI-TOF MS | < 0.1 | [ |
| OMOR, NOCOD, NOMOR | Urine | LLE-CE- ESI-TOF MS | 10 - 300 | [ |
| DHC, NDHC, DHM, NDHM, COD, NMP, NC, MP | Urine | LLE-CE- ESI-TOF MS | <pp | [ |
| NIC and its metabolites | Urine | SPE-CE-ESI-MS/MS | 110 - 2250 | [ |
| Neurotransmitters | CNS | CE-ESI-MS | - | [ |
| ACh, histamine, DA, 5-HT | CNS | CE-ESI-MS | < 50 | [ |
| ACh | Live rats brain | ESI-MS | 5 | [ |
| Volatile organic compounds | Cigarette | PI-TOFMS | - | [ |
| Erlotinib (RO0508231) and its metabolites | Rat tissues | MALDI-MS | 3.76 | [ |
| ACh | Tissues | MALDI-MS | - | [ |
| Loperamide | Mouse brain | MALDI-MS | 25 | [ |
ng/mL;
ng/mg;
nM.